Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HALOZYME THERAPEUTICS, INC.

(HALO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Halozyme Therapeutics, Inc. : A support level that should be taken advantage of

06/10/2021 | 02:54am EDT
long trade
Live
Entry price : 39.66$ | Target : 49.9$ | Stop-loss : 32.6$ | Potential : 25.82%
The medium term support area around 38.84 USD should allow Halozyme Therapeutics, Inc. shares to re-establish an upward trend in the short term.
Investors have an opportunity to buy the stock and target the $ 49.9.
Halozyme Therapeutics, Inc. : Halozyme Therapeutics, Inc. : A support level that should be taken advantage of
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • For a short-term investment strategy, the company has poor fundamentals.

Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart
Subsector Bio Therapeutic Drugs
1st jan.Capitalization (M$)Investor Rating
HALOZYME THERAPEUTICS, INC.-1.26%6 002
GILEAD SCIENCES, INC.15.60%84 469
WUXI APPTEC CO., LTD.24.70%66 143
REGENERON PHARMACEUTICALS10.59%55 327
BIONTECH SE177.34%54 605
VERTEX PHARMACEUTICALS-20.58%48 589
BEIGENE, LTD.26.03%30 138
GENMAB A/S9.30%28 174
ARGENX SE10.54%16 350
HUALAN BIOLOGICAL ENGINEERI..-14.44%10 605
NEUROCRINE BIOSCIENCES, INC..6.20%9 624
More Results

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 400 M - -
Net income 2021 218 M - -
Net Debt 2021 22,0 M - -
P/E ratio 2021 28,8x
Yield 2021 -
Capitalization 6 002 M 6 002 M -
EV / Sales 2021 15,1x
EV / Sales 2022 10,2x
Nbr of Employees 136
Free-Float 98,1%
Upcoming event on HALOZYME THERAPEUTICS, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 42,17 $
Average target price 48,91 $
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
NameTitle
Helen I. Torley President, Chief Executive Officer & Director
Elaine D. Sun Chief Financial Officer & Senior Vice President
Connie L. Matsui Chairman
Michael J. LaBarre Chief Technical Officer & Senior Vice President
Alison A. Armour Senior Vice President-Research & Development